BioTech Medical Exhibiting at ISSA/INTERCLEAN 2009

SAN DIEGO--(Business Wire)--
PURE Bioscience (NASDAQ: PURE) and BioTech Medical LLC today announced that
BioTech Medical will be exhibiting at the annual ISSA/INTERCLEAN trade show
being held this week in Chicago. BioTech Medical`s booth, number 2042, will
feature SpectraSan24, a revolutionary disinfectant powered by PURE`s silver
dihydrogen citrate (SDC) antimicrobial technology.

Andrea L. Goren, Executive Director of BioTech Medical LLC, stated, "We are
focused on building brand recognition through public relations, marketing and
professional endorsements as a foundation for nationwide sales of SpectraSan24
in dozens of business categories in the commercial, institutional and retail
marketplace. This trade show comes at a critical point in our marketing strategy
as we to continue to educate the industry about the unique benefits of
SpectraSan24 as well as capture direct sales and establish additional downline
distribution relationships."

As the worldwide cleaning industry association, ISSA`s global membership
includes more than 5,500 distributor, manufacturer, building service contractor,
and in-house service provider companies. ISSA offers the industry's largest
cleaning shows around the world; a vast array of educational videos and
resources; networking on local, national, and international levels; industry
management standards; legislative and regulatory services; and industry news
specifically focused on the world's cleaning community.

Jefferey Donnell, PURE Bioscience`s Vice President of Business Development,
commented, "BioTech Medical launched a successful public relations campaign that
so far resulted in coverage of SpectraSan24 in more than 30 trade publications
during the last three months. The PR program, combined with the exhibit booth at
ISSA/INTERCLEAN, demonstrates BioTech Medical`s dedication to promoting
SpectraSan24 as a leading brand in the commercial and institutional markets."

SpectraSan 24`s broad spectrum power completely and rapidly eliminates bacteria,
fungi and viruses, including Influenza A. SpectraSan 24 also carries a 30-second
kill time on standard indicator bacteria, a 24-hour residual kill on standard
indicator bacteria, a 2-minute kill time on some resistant strains of bacteria,
a 10-minute kill time on fungi, a 30-second kill time on HIV Type I, and
10-minute kill times on other pathogenic viruses. These claims distinguish the
efficacy of SpectraSan 24 from many of the leading commercial and consumer
products currently on the market, while maintaining lower toxicity ratings.
Based on the EPA toxicity ratings from Category I (high toxicity) down to
Category IV, SpectraSan 24 is a Category IV antimicrobial for which
precautionary labeling statements are not required. This compares with Category
II warning statements for most leading brands of disinfectant products.

About BioTech Medical, LLC

BioTech Medical LLC is a North Canton, Ohio-based division of privately held SCI
Industries, a leading international marketing company. SCI distributes hundreds
of diversified products around the world and has established its success through
product innovation and multi-channel marketing. BioTech Medical`s multiple
business segments are each focused on the distribution of innovative healthcare
products, including the SDC-based SpectraSan24 and Cruise Control hard surface
disinfectants. For more information, please visit www.spectrasan.com.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that
provide solutions to numerous global health challenges. PURE's proprietary high
efficacy/low toxicity bioscience technologies, including its silver dihydrogen
citrate-based antimicrobials, represent innovative advances in diverse markets
and lead today's global trend toward industry and consumer use of "green"
products while providing competitive advantages in efficacy and safety. Patented
SDC is an electrolytically generated source of stabilized ionic silver which
formulates well with other compounds. As a platform technology, SDC is
distinguished from competitors in the marketplace because of its superior
efficacy, reduced toxicity and the inability of bacteria to form a resistance to
it. PURE is headquartered in El Cajon, California (San Diego metropolitan area).
Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate," "project,"
"expect" or similar expressions. These statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and uncertainties that could
cause actual results to differ materially from the forward-looking statements.
Factors that would cause or contribute to such differences include, but are not
limited to, acceptance of the Company's current and future products and services
in the marketplace, the ability of the Company to develop effective new products
and receive regulatory approvals of such products, competitive factors,
dependence upon third-party vendors, and other risks detailed in the Company's
periodic report filings with the Securities and Exchange Commission. By making
these forward-looking statements, the Company undertakes no obligation to update
these statements for revisions or changes after the date of this release.

BioTech Medical Contact:
BioTech Medical LLC
Andrea L. Gorten
800-284-9857 x 4260
andrea@biotechmedicalllc.com
or
PURE Investor Contact:
Bibicoff + MacInnis, Inc.
Terri MacInnis, Dir. of Investor Relations
818-379-8500
terri@bibimac.com
or
PURE Media Contact:
Gutenberg Communications
Michael Gallo
212-239-8594
mgallo@gutenbergpr.com

Copyright Business Wire 2009